/ -- Speaking of the merger of Pfizer's out of patent business (Upjohn) and Mylan that will lead to the formation of a yet to be named new company, Dr. Gurpreet Sandhu, President, Council for Healthcare and Pharma (CHP), said, "The Pfizer (Upjohn)-Mylan newco when formed, has the inherent potential to harness significant complementarities. The new order is all about capturing synergies. This becomes all the more important in the current environment of price reductions, efforts at cost control and the urgency to realise the goal of Universal Healthcare. The combine will bring together huge manufacturing capabilities in India, China, the US and other countries; a large portfolio of generics with a strong pipeline to comprehensively address most disease segments, a well-diversified geographical presence with 75% of sales outside the USA, extremely relevant to address the challenges of most under developed and emerging health systems, in addition to the mature ones.
"At the recently concluded legislative day meetings at the Capitol Hill, D.C, we at the Council for Healthcare and Pharmaceutical had stressed the urgent need to harness global synergies in pharmaceuticals and healthcare, so industry can manufacture high quality generic medicines where best feasible, make them available freely, where most required and at prices that increase access. Research, Manufacturing and Supply chains need to be synergised across industry, to meet these goals and I think the combination is well placed to achieve them."
Disclaimer: No Business Standard Journalist was involved in creation of this content